Literature DB >> 2347859

Results of a brief survey on the prescribing practices for monoamine oxidase inhibitor antidepressants.

C Clary1, L A Mandos, E Schweizer.   

Abstract

Four hundred eighty-five psychiatrists in Pennsylvania and Delaware responded to a survey of prescribing practices for the monoamine oxidase inhibitor (MAOI) antidepressants. Although the low response rate (34%) limited the generalizability of the results, the similarity between respondents and the total sample surveyed argued against gross sampling bias. The authors found that only a minority of psychiatrists (25%) prescribe MAOIs regularly, despite a relatively low rate of reports of serious sequelae from hypertensive crises or other side effects. They also found that a substantial number of psychiatrists who regularly prescribe MAOIs also report prescribing high doses and combining therapy with tricyclics, lithium, neuroleptics, and psychostimulants. These findings have implications for postmarketing research on psychotropic drugs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2347859

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  4 in total

1.  The role of monoamine oxidase inhibitors in current psychiatric practice.

Authors:  Jess G Fiedorowicz; Karen L Swartz
Journal:  J Psychiatr Pract       Date:  2004-07       Impact factor: 1.325

2.  Responding to the Shrinking Scope of Psychiatrists' Prescribing Practices.

Authors:  Richard Balon; Mary K Morreale; Rashi Aggarwal; John Coverdale; Eugene V Beresin; Alan K Louie; Anthony P S Guerrero; Adam M Brenner
Journal:  Acad Psychiatry       Date:  2022-09-19

Review 3.  EMSAM (deprenyl patch): how a promising antidepressant was underutilized.

Authors:  Gregory M Asnis; Margaret A Henderson
Journal:  Neuropsychiatr Dis Treat       Date:  2014-10-06       Impact factor: 2.570

4.  Transdermal selegiline for the treatment of major depressive disorder.

Authors:  Kelly C Lee; Jack J Chen
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.